Genmab A/S (NASDAQ:GMAB) Upgraded at Berenberg Bank

Berenberg Bank upgraded shares of Genmab A/S (NASDAQ:GMABGet Rating) from a sell rating to a hold rating in a research report report published on Friday morning, The Fly reports.

Other research analysts have also issued research reports about the stock. UBS Group raised shares of Genmab A/S from a neutral rating to a buy rating in a research note on Wednesday, March 16th. SVB Leerink lowered their price objective on shares of Genmab A/S from $42.00 to $39.00 and set a market perform rating on the stock in a report on Thursday, February 17th. HC Wainwright reiterated a buy rating and issued a $47.00 price objective on shares of Genmab A/S in a report on Thursday, March 17th. JPMorgan Chase & Co. lowered their target price on shares of Genmab A/S from 3,200.00 to 3,100.00 in a report on Friday, February 25th. Finally, Cowen initiated coverage on shares of Genmab A/S in a report on Monday, May 2nd. They set a market perform rating and a $38.00 target price on the stock. Three analysts have rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Hold and an average target price of $425.50.

Shares of GMAB opened at $28.32 on Friday. Genmab A/S has a twelve month low of $27.42 and a twelve month high of $49.07. The firm’s 50 day moving average price is $34.97 and its two-hundred day moving average price is $36.82. The firm has a market cap of $18.62 billion, a P/E ratio of 38.79, a PEG ratio of 1.34 and a beta of 0.98.

Genmab A/S (NASDAQ:GMABGet Rating) last announced its quarterly earnings results on Wednesday, February 16th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.04. Genmab A/S had a net margin of 35.58% and a return on equity of 14.23%. The firm had revenue of $402.74 million for the quarter, compared to analyst estimates of $387.16 million. As a group, research analysts forecast that Genmab A/S will post 0.77 EPS for the current year.

Institutional investors have recently bought and sold shares of the business. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Genmab A/S by 4,355.2% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 427,699 shares of the company’s stock worth $18,690,000 after buying an additional 418,099 shares in the last quarter. Schonfeld Strategic Advisors LLC lifted its stake in Genmab A/S by 63.4% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 131,469 shares of the company’s stock valued at $5,745,000 after acquiring an additional 51,019 shares in the last quarter. Atria Investments LLC lifted its stake in Genmab A/S by 47.5% during the 3rd quarter. Atria Investments LLC now owns 37,865 shares of the company’s stock valued at $1,655,000 after acquiring an additional 12,188 shares in the last quarter. FNY Investment Advisers LLC bought a new position in Genmab A/S during the 4th quarter valued at $247,000. Finally, Janney Montgomery Scott LLC increased its holdings in Genmab A/S by 10.1% in the 4th quarter. Janney Montgomery Scott LLC now owns 9,451 shares of the company’s stock worth $374,000 after acquiring an additional 870 shares during the last quarter. Hedge funds and other institutional investors own 5.92% of the company’s stock.

About Genmab A/S (Get Rating)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Featured Articles

The Fly logo

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.